Porcine Reproductive & Respiratory Syndrome roadmap:
Vaccines
Roadmap for development of a candidate vaccine for PRRSV
Download PRRSV Vaccine Roadmap4
Inactivated vaccines
Development of cross protective/multivalent killed vaccine
Research Question
- The development of an effective killed virus vaccine that gives broad cross-protection but doesn’t contribute to virus evolution
Research Gaps and Challenges
- Having it multivalent
- Having the protective response involving both VN Abs and CTC
- Initial Ab response following natural infection isn’t protective
Solution Routes
- Generation of a range of recombinant viruses expressing protective Antigens from a range of viruses but lacking the dominant Antigen to which the initial non protective Ab response is generated
- Monitoring the immune response following immunisation with the various candidates
- Challenge experiments with the various vaccine candidates. If a multivalent vaccine isn’t possible then a system for rapid development of autologous vaccines will be needed
Dependencies
- Identifying a combination of antigens for expression by a GM strain of the virus or a common single protective Ag to which immune responses are normally suppressed
- The availability of suitable adjuvants to stimulate strong CTC and VN-Ab responses
Projects
What activities are planned or underway?
Immune responses induced by inactivated Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) vaccine in neonate pigs using different adjuvants
Planned Completion date 01/02/2021
Source Countries:
Netherlands
Modified live vaccine strains of porcine reproductive and respiratory syndrome virus cause immune system dysregulation similar to wild strains.
Planned Completion date 12/01/2024
Source Countries:
Netherlands